ClinicalTrials.gg
TerminatedNCT00670228INTENSIVEUpdated Feb 11, 2011Results posted

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

A Phase 3 interventional study of Insulin Glargine (LANTUS) and Insulin Glulisine (Apidra) in AMI, sponsored by Sanofi. Terminated at 5 sites in 5 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-02-11.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to Negative feasibility assessment of recruiting the planned number of subjects within the study timelines

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Study summary

Primary objective:

To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and insulin glargine, i.e. Intensive Insulin Therapy (IIT), results in reducing infarct size at day 60 versus (vs) Standard Glycemic Care (SGC).

Secondary objectives:

To demonstrate that tight glycemic control using insulin glulisine and insulin glargine reduces markers of inflammation and improves Left Ventricular (LV) function and Cardio-Vascular (CV) outcomes from baseline values, in hyperglycemic subjects with STEMI undergoing Percutaneous Coronary Intervention (PCI).

02

Conditions studied

  • AMI
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women = or > 35 years of age presenting to the hospital with hyperglycemia (plasma glucose >140 mg/dL) and Primary Anterior wall ST-Elevation Myocardial Infarction (AW STEMI)
  • No history of illicit drug abuse in past year
  • A minimum of 30 minutes but \< or = 6 hours of continuous pain/symptoms immediately prior to presentation
  • Subjects who will undergo primary percutaneous coronary intervention (PCI)
  • At least 2 contiguous precordial leads demonstrating at least 2 mm of ST-segment elevation consistent with anterior wall MI
  • Signed and HIPAA documentation (US only) prior to participation in the study
  • Subjects ability and willingness to adhere to and be compliant with study protocol

Exclusion criteria

Exclusion Criteria:

  • A prior history of Myocardial Infarction (MI)
  • Subjects who have received any thrombolytic therapy during the current hospital admission
  • Severe Heart Failure or cardiogenic shock (Killip class 3 or 4) by history or present at the time of screening
  • Subjects with a plasma glucose >400 mg/dL or diabetic ketoacidosis (DKA)
  • History of Type 1 diabetes
  • Active bleeding
  • Active , chronic or other medical conditions likely to result in death over the next one year
  • Recent hypotension requiring inotropic support in the past 30 days
  • Participation in another clinical research study in the past 30 days
  • Pregnant or lactating women (women of must have a negative pregnancy test at study entry and a medically approved method)
  • Unwilling to give
  • Subjects directly involved in the conduct of the study
  • Known to insulin glargine or glulisine
  • to MRI: a)Intracranial aneurysm clips (Unless the investigator is certain that it is made of non-ferromagnetic material such as titanium)b)Intra-orbital metal fragments c)Any electrically, magnetically or mechanically activated implants (including cardiac pacemakers, biostimulators, neurostimulators, cochlear implants, and hearing aids) d)Warning about Gadolinium-based contrast agents (GBCAs) Exposure to GBCAs increases the risk for nephrogenic systemic fibrosis (NSF). Therefore the following subjects should be excluded from the trial based on a history and/or laboratory tests:

    • acute or chronic severe renal insufficiency ( \<30 mL/min/1.73m2), as calculated by the MDRD (Modification of diet in Renal Disease) equation, or
    • acute renal insufficiency of any severity
  • Subjects with blood pressure > or = to 200/110 mmHg at time of randomization
  • Subjects with a high degree of non-transient AV (Atrio-Ventricular) block

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    Intensive Insulin Therapy (IIT)

    In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.

    Drug: Insulin Glargine (LANTUS) · Drug: Insulin Glulisine (Apidra)

  • Active comparator
    Standard Glycemic Care (SGC)

    In SGC arm subjects assigned to "standard of care" received subcutaneous regular insulin per sliding scale.

    Drug: Standard Therapy

Interventions

  • Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL

  • Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight. Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL.

  • DrugStandard Therapy

    Standard insulin therapy titrated to blood sugar control

    Also known as: multiple insulins per hospital protocol

06

What researchers measure

Primary outcomes

  1. Infarct Size Absolute Change From Baseline at Day 60

    Infarct size is measured by cardiac Magnetic Resonance Imaging (MRI) as the percentage of Left Ventricular (LV) mass.

    Time frame: From baseline at Day 60

Secondary outcomes

  1. Left Ventricular (LV) Function Evaluated by Cardiac Magnetic Resonance Imaging (MRI)

    Due to study early termination and the limited number of randomized subjects, descriptive statistics for the Day 3 Ejection Fraction were selected for presentation instead of for Day 60 as initially planned.

    Time frame: At Day 3

  2. Occurrence of the Major Adverse Cardiovascular Events (MACE)

    MACE: Cardiac death, New onset or worsening congestive heart failure (\>24 h post-admission) event evaluating using New York Heart Association (NYHA) Class II or greater Non-fatal Myocardial Infarction, Severe arrhythmia, Stroke/TIA (Transient Ischemic Attack), Cardiogenic shock, Catheterization/revascularization, Unstable angina leading to hospitalisation

    Time frame: At Day 60

  3. Biomarkers of Inflammation Measurement: CRP (C-Reactive Protein)

    Time frame: At Day 60

07

Results

Posted Feb 11, 2011
Limitations and caveats
Early termination leading to small numbers of subjects analyzed. Only descriptive statistics were presented for primary and key secondary efficacy endpoints. The analysis focused on a review of safety Adverse Events (AEs) data.

Participant flow

Multicenter study: 60 out of the 90 centers planned were initiated. Only 17 centers randomized patients (i.e. 7 sites in the United States, 5 sites in Argentina, 3 sites in Brazil and 2 sites in Mexico).

Participant flow — Overall Study
MilestoneIntensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)
Started1815
Completed1312
Not completed53
Withdrew: Adverse event10
Withdrew: Death or mace01
Withdrew: Not treated22
Withdrew: Not meeting the selection criteria20

Outcome measures

PrimaryInfarct Size Absolute Change From Baseline at Day 60

Infarct size is measured by cardiac Magnetic Resonance Imaging (MRI) as the percentage of Left Ventricular (LV) mass.

Time frame:
From baseline at Day 60
Reported as:
Mean · percentage of LV mass change
Infarct Size Absolute Change From Baseline at Day 60
percentage of LV mass changeIntensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)
Infarct Size Absolute Change From Baseline at Day 60-7.84 ± 9.19-15.72 ± 22.41
SecondaryLeft Ventricular (LV) Function Evaluated by Cardiac Magnetic Resonance Imaging (MRI)

Due to study early termination and the limited number of randomized subjects, descriptive statistics for the Day 3 Ejection Fraction were selected for presentation instead of for Day 60 as initially planned.

Time frame:
At Day 3
Reported as:
Mean · percentage of Ejection Fraction
Left Ventricular (LV) Function Evaluated by Cardiac Magnetic Resonance Imaging (MRI)
percentage of Ejection FractionIntensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)
Left Ventricular (LV) Function Evaluated by Cardiac Magnetic Resonance Imaging (MRI)43.08 ± 11.3443.43 ± 6.87
SecondaryOccurrence of the Major Adverse Cardiovascular Events (MACE)

MACE: Cardiac death, New onset or worsening congestive heart failure (\>24 h post-admission) event evaluating using New York Heart Association (NYHA) Class II or greater Non-fatal Myocardial Infarction, Severe arrhythmia, Stroke/TIA (Transient Ischemic Attack), Cardiogenic shock, Catheterization/revascularization, Unstable angina leading to hospitalisation

Time frame:
At Day 60
Reported as:
Number · events
Occurrence of the Major Adverse Cardiovascular Events (MACE)
eventsIntensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)
Severe arrhythmia72
Shock01
Revascularization10
New onset or worsening of congestive heart failure10
Myocardial Infarction (MI)10
Death11
SecondaryBiomarkers of Inflammation Measurement: CRP (C-Reactive Protein)
Time frame:
At Day 60
Reported as:
Mean · mg/L
Biomarkers of Inflammation Measurement: CRP (C-Reactive Protein)
mg/LIntensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)
Biomarkers of Inflammation Measurement: CRP (C-Reactive Protein)2.52 ± 2.102.96 ± 4.07

Adverse events

Collected over Adverse events are collected from the first to the last drug intake + 1 week after the administration of the last intake i.e. end of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intensive Insulin Therapy (IIT)—6/16 (37.5%)10/16 (62.5%)
Standard Glycemic Care (SGC)—3/13 (23.1%)6/13 (46.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventIntensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)
Ventricular TachycardiaCardiac disorders0/162/13
BradycardiaCardiac disorders2/160/13
HypotensionVascular disorders2/160/13
Cardiac Failure CongestiveCardiac disorders0/161/13
Cardiogenic ShockCardiac disorders1/161/13
Pericardial EffusionCardiac disorders1/160/13
PericarditisCardiac disorders1/160/13
Sinus TachycardiaCardiac disorders1/160/13
BronchopneumoniaInfections and infestations1/160/13
PneumoniaInfections and infestations1/160/13
Most frequent other events
Showing 10 of 53
Most frequent other events
EventIntensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)
HypotensionVascular disorders4/160/13
Ventricular ExtrasystolesCardiac disorders0/162/13
NauseaGastrointestinal disorders1/162/13
VomitingGastrointestinal disorders1/162/13
Myocardial InfarctionCardiac disorders2/160/13
ConstipationGastrointestinal disorders2/160/13
Vessel Puncture Site HaematomaGeneral disorders2/161/13
HypokalaemiaMetabolism and nutrition disorders2/160/13
Back PainMusculoskeletal and connective tissue disorders2/161/13
HeadacheNervous system disorders2/161/13

Baseline characteristics

Age Continuous
Age Continuous(years)Intensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)Total
Mean61.11 ± 10.9562.80 ± 11.1261.88 ± 10.89
Sex: Female, Male
Sex: Female, Male(Participants)Intensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)Total
Female628
Male121325
Body Mass Index (BMI)
Body Mass Index (BMI)(Kg/m^2)Intensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)Total
Mean26.95 ± 3.3428.49 ± 3.9227.65 ± 3.64
Diabetes diagnosis at study entry
Diabetes diagnosis at study entry(participants)Intensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)Total
Yes6713
No12820
Duration of Diabetes at study entry
Duration of Diabetes at study entry(Years)Intensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)Total
Mean9.50 ± 9.207.50 ± 6.808.50 ± 7.79
Mean time to Percutaneous Coronary Intervention (PCI)
Mean time to Percutaneous Coronary Intervention (PCI)(minutes)Intensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)Total
Mean110.00 ± 112.69101.54 ± 51.47106.07 ± 88.21
Myocardial Infarction (MI) duration greater than 3 hours
Myocardial Infarction (MI) duration greater than 3 hours(participants)Intensive Insulin Therapy (IIT)Standard Glycemic Care (SGC)Total
No13922
Yes5611
08

Study locations

5 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Col. Coyoacan, Mexico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2008
First posted
May 1, 2008
Start
Apr 2008
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Feb 11, 2011
Last update
Feb 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00670228
Lead sponsor
Sanofi
First posted
May 1, 2008
Start date
Apr 2008
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Feb 11, 2011
Last update
Feb 11, 2011

Study contacts

Clinical Study Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Insulin glulisine

Start the discussion